INTRODUCTION

Filoviruses (the members of the mononegaviral family Filoviridae) cause two diseases recognized by the World Health Organization (WHO): Ebola virus disease (EVD) can be caused by Bundibugyo virus (BDBV), Ebola virus (EBOV), Sudan virus (SUDV), and Taï Forest virus
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immunocompromised nonhuman primates had suggested that the vaccine would be safe in special populations [20] . In other multiple clinical studies in the US, Africa, and Europe, significant adverse events with rVSV-ZEBOV have not been observed [21, 22] . As a direct relationship between vaccine dose and both immunogenicity (as evaluated by antibody titers) and safety (as evaluated by adverse events) is apparent, an acceptable balance between immunogenicity and safety should be determined based on collected clinical data [19] . Antibody titer data from protected individuals in the Guinea Ring Trial may aid in determining optimal antibody titers desired for protection.
In the pipeline
In contrast to rVSV-ZEBOV, VesiculoVax (Profectus Biosciences) is based on a recombinant VSIV that expresses both VSIV G and EBOV GP 1,2 . However, a rearrangement of the gene order in the recombinant backbone results in preferential expression of EBOV GP 1,2 and minimal expression of the VSIV G, which is also truncated [23, 24] . Potential benefits of this candidate vaccine are that the rearrangement of genes also places the VSIV nucleocapsid (N) gene in the fourth position (rather than the wild-type first position), which attenuates the virus [11] .
Recently, researchers from Profectus Biosciences demonstrated that VesiculoVax is efficacious in nonhuman primates against infection with EBOV Makona-C07, which is an isolate obtained during the 2013-2016 Western Africa EVD outbreak [23] . VesiculoVax is produced with GP 1,2 from the EBOV Yambuku-Mayinga isolate obtained in 1976, as are many of the candidate vaccines discussed here. Consequently, the VesiculoVax nonhuman-primate study demonstrates the ability of the vaccine to cross-protect against different EBOV variants to some extent.
Researchers from Profectus Biosciences suggest that VesiculoVax may be safer than other VSIV platforms due to the incorporated attenuation, and a head-to-head comparison between rVSV-TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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ZEBOV and VesiculoVax candidates may therefore be of interest. The VesiculoVax platform has successfully entered a clinical trial with an antigen insert (human immunodeficiency virus-1
[HIV-1]) other than EBOV, and therefore theoretically should be poised to transition to the clinic if funding were provided (NCT01438606).
Respirovirus Vectors
Respiroviruses (Mononegavirales: Paramyxoviridae: Respirovirus) are single-stranded, negative-sense, RNA viruses that are actively being explored as potential vaccine vectors. Early studies examining the utility of recombinant human parainfluenza virus 3 (HPIV-3) as a vaccine vector demonstrated that multiple glycoproteins could be inserted into the viral backbone. The utility of insertion was impacted by the number and position of insertions and by whether the resulting protein was incorporated into packaged virions [25] . Potential benefits of HPIV-3 as a vector include its genomic stability, ease of production, and the efficiency with which foreign inserts are expressed [26, 27] . However, as for adenovirus platforms, pre-existing immunity to HPIV-3 may reduce vaccine efficacy. Preclinical efforts are underway to circumvent the issues of pre-existing immunity [28, 29] .
HPIV3-EBOVZ GP
Results from preclinical studies in HPIV-3-immune guinea pigs with EBOV GP 1,2 -expressing HPIV-3 have suggested that while pre-existing immunity to the vector suppressed vector replication, the animals nonetheless mounted a robust immune response to the EBOV GP 1,2 [30] .
In contrast, in nonhuman primates, low levels of vector replication were detectable despite preexisting immunity to HPIV-3 [31] . While immunogenicity was initially reduced in vectorimmune monkeys, the IgG, IgA, and neutralizing antibody titers to EBOV GP 1,2 were essentially NIAID is sponsoring clinical trials with an HPIV-3-based vaccine, "HPIV3-EbovZ GP" (NCT02564575). Perhaps the most unique and intriguing characteristic of this candidate vaccine is that the vaccine is administered intranasally; all other vaccines currently in clinical trials are administered intramuscularly. The potential benefits of intranasal administration are the ease of administration as well as the effective induction of mucosal immunity. Mucosal immunity may be of particular importance in filovirus disease outbreaks during which the vast majority of infections are thought to occur through mucosal exposure to contaminated bodily fluids. The current Phase I study is examining two doses of HPIV3-EbovZ GP administered twice at a 4-8 week-interval. Viremia, the duration of HPIV-3 shedding, and safety will be assessed in the volunteers.
REPLICATION-INCOMPETENT, VECTORED VACCINES
Adenovirus vectors
Adenoviruses (Adenoviridae) have been developed as vaccine vectors for multiple antigens, but pre-existing immunity to the selected adenovirus may impact vaccine efficacy [33] [34] [35] . Vaccines based on adenovirus backbones may be ineffective if a patient's pre-existing immunity to the adenovirus stifles the immune response to the intended target antigen [33] . Moreover, preexisting immunity to the adenovirus 5 (Ad5; species Human mastadenovirus C) backbone actually seemed to have a negative effect on prognosis in an HIV-1/AIDS vaccine trial [36, 37] .
Nonetheless, one of the first EVD vaccines to enter clinical trials was, in fact, an adenovirusbased vaccine targeting EBOV (VRC-EBOADV018-00-VP) [38, 39] . Subsequent research has examined the properties of various adenovirus vectors on vaccine immunogenicity and efficacy, indicating that concerns about adenovirus-based vaccines can be mitigated by careful selection of the backbone virus [40, 41] . Two of the current, advanced EVD candidate vaccines that are based on adenoviruses circumvent the issue of pre-existing immunity either by enlisting a chimpanzee adenovirus 3 (ChAd3; species Human mastadenovirus C) vector or a vetted human vector against which the population at large has limited pre-existing immunity. Additionally, preexisting immunity to adenoviruses may be abrogated by administering the vaccine orally, a route Provincial Centers for Disease Control and Prevention in China (NCT02326194, NCT02575456, NCT02533791). All of these adenovirus backbones were tailored to become replicationincompetent by deleting the E1 regions [48, 49] . EBOV GP 1,2 is encoded by the adenovirus backbone and is therefore expressed upon entry of a target cell by the encoded adenovirion; GP 1,2 is not located on the adenovirus particle surface as in the case of VSIV-based vaccines [33] .
ChAd3.EBOZ
The ChAd3 backbone is an effective antigen delivery system and has been tested as a candidate vaccine against multiple pathogens [50, 51] . Two separate ChAd3-based filovirus vaccines were developed by the NIAID VRC. VRC-EBOADC069-00-VP (ChAd3-EBO) expresses both the EBOV and the related Sudan virus (SUDV) GP 1,2 s in two separate vectors, mixed at a 1:1 ratio.
VRC-EBOADC076-00-VP (ChAd3-EBOZ), in contrast, only includes EBOV GP 1,2 . Both candidate vaccines have been evaluated in Phase I studies. ChAd3-EBOZ has moved on to Phase II trials and the Phase III PREVAIL trial, and the vaccine is licensed by GlaxoSmithKline (GSK) as GSK3390107A.
ChAd3-EBOZ was among the first EVD candidate vaccines evaluated for duration of immunity in nonhuman primates. Investigators found that immunity waned in crab-eating macaques after a single vaccination and therefore included a booster vaccination with an MVA-vectored vaccine [52] . Potentially stemming from these data and the immunogenicity data collected during an early Phase I trial [53] , several ongoing clinical trials are utilizing a heterologous prime-boost Current clinical studies are evaluating the impact of timing of the boost vaccination, directly comparing administration of the boost (MVA-EBOZ) at days 14 and 28 and even as early as day 7 (NCT02451891, NCT02240875). Moreover, different combinations of the two candidate vaccines (ChAd3-EBOZ, MVA-EbolaZ) and different dose levels are being evaluated to determine the most immunogenic combination. Investigators from a recently published Phase I study performed in Mali and the US suggested that ChAd3-EBOZ may be adequate for shortterm protection, as, for example, in a ring vaccination setting. However, a boost with an MVA vaccine would likely provide more durable protection [54] . Notably, the highest ChAd3-EBOZ dose tested, 10 11 particle units (pu), was selected as the optimal dose level [54] .
ChAd3-EBOZ is currently being evaluated in clinical trials in Africa, including in Mali, Senegal, Uganda, and Liberia (NCT02368119, NCT02485301, NCT02548078, NCT02267109, NCT02485912, NCT02354404, NCT02344407). Critically, ChAd3-EBOZ is the comparator treatment arm to rVSV-ZEBOV treatment arm in the PREVAIL study; data from the PREVAIL study that directly compare the immunogenicity of the two vaccines will be of great interest to the filovirus vaccine community. Historically, the adenovirus-based vaccine was thought to rely on a CD8 T-cell response for maximum efficacy, whereas a humoral response is thought to be the primary efficacy correlate of rVSV-ZEBOV [55] [56] [57] .
As a non-replicating vaccine, ChAd3-EBOZ has not caused the concerning adverse events seen with rVSV-ZEBOV; however, ChAd3-EBOZ also appears to be inadequately immunogenic as a single vaccination [53, 54, 58] . In some EVD outbreak situations, administration of a booster TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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vaccination may not be feasible and will certainly be more costly than an efficacious single vaccination. Moreover, adenovirus based vaccines will not only require multiple vaccinations, but will require heterologous vaccinations. The immune response mounted to the adenovirus upon primary vaccination will reduce uptake of the adenovirus vaccine, reducing expression of the antigen, and therefore reducing or eliminating the immune response to the antigen [39, 59] .
Inadequate immunogenicity of a homologous adenovirus prime/boost regimen was indeed observed in nonhuman primate studies with ChAd3-EBOZ, and makes heterologous prime/boost vaccination a requirement for durable protection with this vaccine [52] . Overall, ChAd3-EBOZ appears to be an efficacious and safe candidate vaccine, but the logistical complications associated with administering a heterologous boost may reduce its impact in endemic regions. Africa, including sites in Tanzania, Uganda, Kenya, and Sierra Leone. Additionally, Ad26.ZEBOV/MVA-BN-Filo vaccination is being studied in children, the elderly, and immune compromised individuals (NCT02564523, NCT02661464, NCT02509494). Ad26.ZEBOV is associated with a strong safety profile, with immunogenicity its most significant potential pitfall.
As with many of these vaccine candidates, the low quantity of peer-reviewed publications on the products does not reflect the number of clinical trials completed or ongoing. Presumably, a significant amount of accumulated data will become available within the next year, but for now one must unfortunately rely on (potentially biased) company reports. For the Ad26.ZEBOV/MVA-BN-Filo vaccine combination, Janssen has created a project called EBOVAC (http://www.ebovac.org/), which apparently serves to collate and present data acquired from the numerous ongoing clinical trials of EVD candidate vaccines.
Ad5-EBOV
Despite concerns regarding Ad5-vectored vaccines, one Ad5-based EVD vaccine (Ad5-EBOV) is in the clinic both in China and in Sierra Leone. The vaccine is sponsored by the Jiāngsū Provincial Centers for Disease Control and Prevention and features EBOV GP 1,2 encoded by the Ad5 backbone. One unique attribute of this vaccine is the use of a glycoprotein gene encoding GP 1,2 of the EBOV Makona-C15 isolate rather than EBOV Yambuku-Mayinga, with the aim to TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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increase efficacy against the 2013-2016 Western Africa EBOV variant [64] . Investigators assessed pre-existing immunity of volunteers to the Ad5 backbone and found that a majority did indeed have antibodies against Ad5 [64] . The investigators also evaluated anti-EBOV GP 1,2 titers after vaccination, comparing the titers of individuals with high vs. low pre-existing immunity to Ad5. Pre-existing immunity to Ad5 reduced anti-EBOV GP 1,2 antibody titers significantly, but administration of a higher vaccine dose could potentially ameliorate this reduction [64] .
Considering that Ad5 immunity is quite prevalent in the African population, the use of Ad5-EBOV will only be advocated if immunogenicity concerns in the endemic population are overcome [65] . A Phase 2 study is now underway in Sierra Leone to compare the efficacy of two vaccine dosages (NCT02575456).
In the pipeline
The development of an orally or intranasally administered Ad5-vectored EVD vaccine has been pursued [66, 67] , and a recent study suggests that sublingual administration of an adenovirusbased vaccine may provide durable protection at least in nonhuman primates [68] . Oral administration of a live adenovirus-vectored vaccine abrogates the relevance of pre-existing vector immunity, resulting in a robust immune response to the delivered antigen [42, 43, 69, 70] .
The US company Vaxart, which is currently evaluating an oral adenovirus-based influenza vaccine in a Phase I clinical trial (NCT02547792), has also developed an oral adenovirus-based EVD vaccine with plans to enter clinical trials.
Poxvirus Vectors
MVA is a replication-incompetent, attenuated vector developed from vaccinia virus (Poxviridae:
Chordopoxvirinae: Orthopoxvirus) [71] . Antigens encoded by the vector are expressed in host TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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target cells upon infection [71] . MVA is itself stockpiled as a potential vaccine against smallpox (caused by the closely related variola virus), but it has also been used as a vector in the development of vaccines against many diseases, including malaria, hepatitis C, influenza, and, of course, filovirus diseases [50, 72, 73] .
MVA-vectored vaccines have been used as heterologous boosts in multiple clinical trials, generally in combination with an adenovirus-based vaccine [74] . Bavarian Nordic's MVA-BN- [54] .
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Few data have been published for MVA-BN-Filo alone, as this vaccine was developed specifically in response to the 2013-2016 Western Africa EVD outbreak. Bavarian Nordic has actively pursued the inclusion of adjuvants, including double-stranded RNA, into their vaccine platform in the past, but it is unclear whether these efforts will extend to the filovirus products [75] . Current clinical trials are examining the possibility of including MVA-BN-Filo as a prime as well as a boost with the Ad26.ZEBOV partner vaccine (NCT02376400, NCT02325050). The combinatorial vaccine regimen is currently being evaluated in clinical trials at multiple sites in Africa, the US, and Europe. Janssen's EBOVAC project will presumably be summarizing and releasing data as they become available. antibody response in nonhuman primates [52] . However, administering the MVA vaccine as a boost after a ChAd3-EBOZ prime resulted in 100% survival and enhanced immune responses, laying the groundwork for subsequent clinical studies [52] .
MVA-EbolaZ
In the pipeline
In an effort to develop a filovirus vaccine with an added public-health benefit-and potentially with more appeal to pharmaceutical companies-NIAID has developed a vectored Ebola virus GP 1,2 vaccine based on rabies virus (Mononegavirales: Rhabdoviridae: Lyssavirus). This vaccine
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has been developed as a replication-competent (BNSP333-GP), replication-deficient (BNSPdeltaG-GP), and chemically inactivated vaccine (INAC-BNSP333-GP) [76] . In a nonhuman primate study comparing the vaccines, animals received a single vaccination of the replication-competent or replication-deficient vaccines, or two doses of the inactivated vaccine.
Animals mounted antibody responses to both rabies virus G and Ebola virus GP 1,2 . All of the animals vaccinated with the replication-competent vaccine survived EBOV exposure with this single vaccine dose, whereas the attenuated and inactivated vaccines provided partial protection [77] . Survival seemed to be associated with a stronger IgG1 (as opposed to IgG2) response and a higher avidity antibody response [77] . Ongoing efforts to improve efficacy include a codonoptimized EBOV GP 1,2 and an adjuvant with the inactivated vaccine [78] .
DNA VACCINES
DNA vaccines are inexpensive, safe, and easy to produce; however, the pitfall of the platform is that DNA vaccines are often poorly immunogenic by intramuscular administration.
Electroporation is currently used to deliver many DNA candidate vaccines into the nucleus of the target cells, which is required for effective antigen production and therefore immunogenicity. While the safety profile, cost effectiveness, and ease of production make DNA vaccines attractive candidates, the difficulty in vaccine administration is a serious hurdle to their licensure.
It is impractical to deploy hundreds of electroporation instruments to remote areas in Africa, where instrument failure or poor maintenance could mean that the vaccine cannot be TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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administered. Nonetheless, the possibility that a more efficient delivery technology will be developed would make DNA vaccines more practical. Moreover, if vaccination of only a small number of people were required to perhaps ring-vaccinate to contain a new EVD outbreak, DNA vaccines offer an easily amenable platform that could be made variant-specific and administered effectively to a small number of at-risk individuals.
NIAID-Sponsored DNA vaccines (VRC-EBODNA023-00-VP, VRCEBODNA012-00-VP, and
VRCMARDNA025-00-VP)
NIAID sponsored three clinical trials for their DNA candidate vaccines between 2003 and 2013.
Two of these trials were Phase 1 trials in the US, whereas the third was conducted in Uganda.
The vaccines in all studies were administered by Biojector, a needle-free injection system. The first trial tested an ebolavirus DNA vaccine (VRCEBODNA012-00-VP) that included three plasmids expressing EBOV GP 1,2 , SUDV GP 1,2 , and EBOV NP. The expressed GP 1,2s lacked their transmembrane domains in an effort to increase release of the proteins from the expressingcell membrane after expression [79] . VRCEBODNA012-00-VP was administered as part of a prime-boost regimen with an early Ad5-based vaccine as the boost, also produced by NIAID.
The impetus for these studies was a nonhuman primate study wherein three vaccinations with the DNA vaccine, followed by a single vaccination with the Ad5 vaccine, resulted in protection from EBOV infection [49] . After vaccination, all volunteers had seroconverted to at least one of the antigens [79] .
A second generation DNA vaccine, VRC-EBODNA023-00-VP, included two plasmids expressing full-length EBOV and SUDV GP 1,2 , and it was tested in parallel with a DNA vaccine for Marburg virus disease, VRCMARDNA025-00-VP, which expressed full-length MARV GP 1,2 TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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Ebola virus vaccines 19 [80] . After three vaccinations, only 56% of subjects had seroconverted to the Ebola virus GP 1,2 and 89% to the Sudan virus GP 1,2 , suggesting that the DNA vaccines had not been administered effectively [80] . The potential impact of a heterologous boost on immunogenicity was not evaluated. Because the safety data from the study were reassuring, these vaccines went on to be evaluated in a Phase 1b trial in Uganda. Volunteers received 4 mg of EBOV DNA vaccine, MARV DNA vaccine, or both (NCT00997607) using Biojector 2000. While the safety profile of the vaccine was acceptable, even after three vaccinations the immune response of volunteers was poor, and antibody titers had nearly returned to baseline levels by 44 weeks after vaccination [81] .
Inovio-developed DNA Vaccines (INO-4201, INO-4202, and INO-4212)
Inovio vaccination. Administration of the vaccines will be intramuscular, but the injection will be followed by electroporation (NCT02464670) [82] . Data from these studies should become available in late 2016.
SUBUNIT VACCINES
It has long been known that ebolavirus GP 1,2 is the required antigen for obtaining protective immunity [28, 83, 84] . All of the vaccines in clinical trials are using GP 1,2 as their antigen, and measurement of GP 1,2 -specific immune responses will likely be the ultimate correlate of protection. Naturally, investigators have therefore looked at the potential utility of protein-based TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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and subunit vaccines. A GP 1,2 -based subunit vaccine would face the hurdles of immunogenicity and manufacturing. Protein-based vaccines lack "danger signals" and typically are poorly immunogenic in the absence of a vaccine adjuvant. In addition, GP 1,2 is a notoriously difficult protein to produce and, due to its cytotoxicity, cell lines producing GP 1,2 are also difficult to maintain. Despite these obstacles, one protein-based platform has advanced into Phase 1 clinical trials (NCT02370589).
Ebola virus GP 1,2 with Matrix-M adjuvant
Novavax has produced an EBOV Makona GP 1,2 nanoparticle vaccine that is adjuvanted with proprietary Matrix-M. Matrix-M, according to Novavax, is a phospholipid base with synthetic cholesterol and saponin. There are multiple vaccine adjuvants that are immune-stimulating complexes (ISCOMs) like Matrix-M, and this class of adjuvants is associated with eliciting strong humoral and cellular responses [85] . To produce the vaccine, Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV; Baculoviridae: Alphabaculovirus) expressing the antigen of interest, in this case EBOV GP 1,2 , is used to infect Spodoptera frugiperda Sf9 insect cells. GP 1,2 is then expressed on the surface of infected cells. The cells are lysed, and the GP 1,2 is collected for formulation with the adjuvant. Primary publications on this product have not yet been released, but a similar approach has been used by Novavax for its human respiratory syncytial virus vaccine products [86] . Data from the ongoing Phase 1 trial should become available soon.
In the pipeline
The US Army Medical Research Institute of Infectious Disease (USAMRIID) developed a filovirion-like particle more than twenty years ago [84, [87] [88] [89] [90] [91] [92] . These virion-or ("virus")-like TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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particles (VLPs) have alternately been produced in Sf9 cells via a baculovirus system, much like the Novavax product, or in human 293 cell lines. VLPs have been shown to be highly immunogenic and confer protection in the absence of adjuvants to rodents exposed to rodentadapted EBOV [93, 94] . Inclusion of adjuvant, however, results in significant dose sparing and is required for achieving protection in nonhuman primates [95] [96] [97] [98] [99] . The VLP platform was anticipated to move forward to clinical trials, but manufacturing issues have hampered its progression.
CONCLUSIONS
In this review, we refrained from delving too deeply into immunogenicity data collected from the various past and ongoing vaccine trials due to the lack of standardized assays by which samples from different studies can be compared. Efforts are underway to standardize an enzyme-linked immunosorbent assay for antibody titer evaluation, as well as an assay to evaluate neutralizing antibody titers [100, 101] . Vaccine development would benefit considerably from agreement by the various sponsors to have an independent organization run comparative immunological assays with their study samples.
For deployment to regions affected by filovirus infection, cold-chain requirements should be considered. These requirements are difficult to adhere to in parts of Africa, where supply of electricity and therefore refrigeration is not reliable. Vaccines that are effective after lyophilization or storage at room temperature may provide a competitive benefit over those that require colder storage temperatures. While pre-existing immunity to the Ad5 vector may affect the efficacy of the vaccine, use of Ad5-EBOV in a lyophilized format is at least suggestive that adenovirus-based vaccines can be efficacious after lyophilization [64] . Other vaccines discussed TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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here are undergoing stability studies or have been demonstrated to be stable at refrigeration conditions. Ebola virus and other filoviruses cause severe disease with a rapid onset. The development of a vaccine rapidly inducing immunity via a single vaccination would be ideal. The requirement of heterologous boosts for the adenovirus-based vaccines is a drawback in terms of production but also in terms of practical administration. While a single vaccination would be ideal, even a homologous boost would be preferable to a heterologous boost. In this area, VSIV-based vaccines are promising.
A third point to consider in developing an EVD vaccine for an African population is that the microbiome, nutritional status, and pre-existing immunity of vaccinees are quite distinct from those of the European or American populations. These differences between the developed world and the developing world may impact vaccine efficacy. Thus, while an orally administered vaccine would seem to be ideal for its ease of administration and lack of cold-chain requirements, there is evidence that oral vaccines fail in populations with disturbed microbiota, poor nutrition, and high intestinal inflammation [102] [103] [104] . Additionally, developers of vectored vaccines should consider the pre-existing immunity of the target population, which may differ from that of the country in which the product is developed.
Finally, the vast majority of EVD vaccines currently evaluated in clinical trials are administered intramuscularly; the single exception is HPIV3-EbovZ GP. Little research has been performed to ascertain whether intramuscular vaccine administration of a vaccine will protect against mucosal exposure, which is the most likely route of exposure to a filovirus during a natural disease outbreak. rVSV-ZEBOV administration in nonhuman primates via intranasal and oral TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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administration has been compared to intramuscular administration [105] . Animals survived intramuscular exposure to EBOV regardless of vaccination route, and intranasal administration elicited higher peripheral IgA and IgG titers compared to that observed with intramuscular administration. Unfortunately, IgA titers in mucosal tissues were not evaluated, nor was protection from mucosal infection. An earlier nonhuman primate study using VSIV-vectored Marburg virus or EBOV GP 1,2 , however, demonstrated vaccine efficacy against aerosol exposure to homologous virus [106] . Nonhuman primate studies using adenovirus-vectored filovirus vaccines have also demonstrated protection against aerosolized agent, but data on aerosol exposure with the current clinical candidates are not yet available [107] .
EXPERT COMMENTARY
The variety of EBOV vaccines currently in clinical trials is astounding considering the state of EBOV vaccine research only 5 or even only 3 years ago. The candidate vaccines currently in the clinic are based on multiple platforms and have varying benefits and pitfalls. From the current candidate vaccines, more than one candidate will likely have an acceptable safety record allowing advance to product licensure. Certainly there are benefits to advancing more than one candidate, as different vaccines may be more valuable in some settings than in others. Vaccines for an emerging outbreak should be fast acting and easily disseminated to remote regions. In contrast, multiple vaccine boosts might be acceptable for healthcare workers or military personnel if the vaccine is administered well in advance of deployment to an outbreak region.
From a biodefense standpoint, protecting a target population from aerosolized EBOV is desirable. A specialized vaccine for enhanced mucosal immune protection may be preferable for at-risk personnel.
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For a re-emerging pathogen like EBOV, researchers have a unique opportunity to develop the best possible vaccine. If history is any indication, several years will pass before the next major EVD outbreak occurs. During that time, researchers could harness the knowledge gained from the current clinical candidates and, in collaboration with the institutes and agencies that developed them, work to develop an optimized vaccine candidate. Potentially, the next filovirus disease outbreak may not be due EBOV, but could be due to another known or unknown filovirus that will require the rapid production of a new vaccine. To that end, optimization of the vaccine platform for rapid modification of the expressed antigen would be a valuable research aim for investigators.
While one hopes that the next filovirus disease outbreak is years away, we could conceivably see an increase in the incidence of filovirus disease. As urban communities continue to expand and villages grow, we are increasingly encroaching on the territory of animals and other organisms that could harbor human pathogens. Naturally, our risk of exposure will increase. For the vaccine field in general, the impetus should be on developing vaccine platforms that can be rapidly modified to counter emerging threats.
FIVE-YEAR VIEW
The advancement of EBOV vaccines accelerated considerably during the recent Western Africa EVD outbreak, and clinical trials focused on safety and immunogenicity continue in Africa and the Western World. Several of these candidates will likely have an acceptable safety profile.
Concurrently, efforts will proceed for improving these vaccines. These efforts may include TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited. TR-16-115 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
